Kailera Therapeutics initiated with an Outperform at Evercore ISI

Evercore ISI analyst Umer Raffat initiated coverage of Kailera Therapeutics (KLRA) with an Outperform rating and no price target Kailera is “making waves in the GIP-GLP space with impressive early-stage data,” says the analyst, who notes that a head-to-head trial against semaglutide is underway in China, with data expected in early 2027. Initial expectations suggest Kailera could outperform semaglutide by at least 6 percentage points in weight loss, though “the full potential of oral formulations may take time to unfold,” the analyst added.